mRNA-CR-04 / GSK - LARVOL DELTA

Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18-49 Years of Age. (PubMed, Open Forum Infect Dis) - P1 | "The investigational mRNA-CR-04 vaccine was generally well tolerated, and all doses induced a robust immune response against the encoded antigen at doses ranging between 3 and 100 µg. Further investigation of potential vaccine candidates using this novel mRNA platform is warranted."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=114 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | N=72 ➔ 114

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases